EA201290972A1 - Способы уменьшения симптомов у субъектов с применением лекарственных форм для однократного введения с постепенно снижающимися скоростями высвобождения - Google Patents

Способы уменьшения симптомов у субъектов с применением лекарственных форм для однократного введения с постепенно снижающимися скоростями высвобождения

Info

Publication number
EA201290972A1
EA201290972A1 EA201290972A EA201290972A EA201290972A1 EA 201290972 A1 EA201290972 A1 EA 201290972A1 EA 201290972 A EA201290972 A EA 201290972A EA 201290972 A EA201290972 A EA 201290972A EA 201290972 A1 EA201290972 A1 EA 201290972A1
Authority
EA
Eurasian Patent Office
Prior art keywords
relations
subjects
ways
application
gradually decreasing
Prior art date
Application number
EA201290972A
Other languages
English (en)
Inventor
Чарльз Е. Дилиберти
Ану Махашабде
Original Assignee
Тева Вимен'С Хелс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Вимен'С Хелс, Инк. filed Critical Тева Вимен'С Хелс, Инк.
Publication of EA201290972A1 publication Critical patent/EA201290972A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin

Abstract

Настоящее изобретение относится к способам уменьшения симптомов, связанных с резким снижением уровня эндогенного или экзогенного химического вещества у субъекта, включающим: (а) введение субъекту лекарственной формы для однократного введения, содержащей активный агент, при этом скорость высвобождения активного агента из лекарственной формы для однократного введения постепенно снижается в течение введения; и (b) удаление лекарственной формы для однократного введения из организма субъекта после того, как скорость высвобождения активного агента достигает или становится меньше конечного порогового уровня для симптома.
EA201290972A 2010-05-05 2011-05-05 Способы уменьшения симптомов у субъектов с применением лекарственных форм для однократного введения с постепенно снижающимися скоростями высвобождения EA201290972A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33177510P 2010-05-05 2010-05-05
PCT/US2011/035402 WO2011140375A1 (en) 2010-05-05 2011-05-05 Methods of reducing symptoms in subjects using single dosage forms with tapering release rates

Publications (1)

Publication Number Publication Date
EA201290972A1 true EA201290972A1 (ru) 2013-08-30

Family

ID=44902095

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290972A EA201290972A1 (ru) 2010-05-05 2011-05-05 Способы уменьшения симптомов у субъектов с применением лекарственных форм для однократного введения с постепенно снижающимися скоростями высвобождения

Country Status (8)

Country Link
US (1) US9220692B2 (ru)
EP (1) EP2566877A4 (ru)
CN (1) CN103154016A (ru)
CA (1) CA2798220A1 (ru)
EA (1) EA201290972A1 (ru)
IL (1) IL222837A0 (ru)
MX (1) MX2012012695A (ru)
WO (1) WO2011140375A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013090117A1 (en) * 2011-12-13 2013-06-20 Arstat, Inc. A multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3040978A1 (de) 1980-10-28 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Vaginalring
US5004610A (en) * 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
GB9522403D0 (en) 1995-11-01 1996-01-03 Hoechst Roussel Ltd Intravaginal drug delivery device
CN1234350C (zh) * 2001-07-18 2006-01-04 上海市计划生育科学研究所 阴道环或宫内节育器上用的雌激素贴膏
EP2082737B1 (en) 2002-03-04 2014-12-31 Merck HDAC Research, LLC Methods of inducing terminal differentiation
EP1494679A4 (en) 2002-04-03 2009-10-28 Barr Lab Inc STEP-BY-STEP ESTROGENTHERAPY
WO2006026844A1 (en) 2004-09-09 2006-03-16 Biolab Sanus Farmacêutica Ltda. Hormone delayed release composition on the basis of polyorganosiloxanes or ethylene vinyl acetate resp. process for its manufacture
US20100040671A1 (en) * 2008-08-12 2010-02-18 Ahmed Salah U Intravaginal Devices With a Rigid Support, Methods of Making, and Uses Thereof
RU2505291C2 (ru) * 2009-06-24 2014-01-27 СТРАТЕДЖИК САЙЕНС ЭНД ТЕКНОЛОДЖИЗ, ЭлЭлСи Топическая композиция, содержащая ибупрофен

Also Published As

Publication number Publication date
EP2566877A1 (en) 2013-03-13
EP2566877A4 (en) 2013-10-09
CA2798220A1 (en) 2011-11-10
WO2011140375A1 (en) 2011-11-10
CN103154016A (zh) 2013-06-12
US20110274740A1 (en) 2011-11-10
IL222837A0 (en) 2012-12-31
US9220692B2 (en) 2015-12-29
MX2012012695A (es) 2013-02-26

Similar Documents

Publication Publication Date Title
GB2491328A (en) Immediate/delayed drug delivery
GB2491327A (en) Delayed prolonged drug delivery
EA201391701A1 (ru) Назальные тестостероновые гели с контролируемым высвобождением, способы перназального введения и предварительно заполненные многодозные аппликаторные системы для перназального введения
GB2491775A (en) Pulsatile drug release
MX2019003467A (es) Formulaciones y metodos para la administracion vaginal de antiprogestinas.
EA201270167A1 (ru) Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения
NZ774222A (en) Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
MX2010009447A (es) Uso de antagonistas de lhrh a dosis no castrantes.
MX2013002146A (es) Formulaciones farmaceuticas que utilizan antioxidantes solubles en agua.
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
MY174894A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
MX2014005996A (es) Anticuerpo anti - adrenomedulina (adm) o fragmento de anticuerpo anti - adm o un andamio no ig anti - adm para usarse en terapia.
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
NZ715686A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
AR086395A1 (es) Envase para el tratamiento de patologias
MY185108A (en) Method for treatment of labor arrest
EA201600497A1 (ru) Оптимизированная фармацевтическая композиция для лечения воспалительных изменений пищевода
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
EA201290972A1 (ru) Способы уменьшения симптомов у субъектов с применением лекарственных форм для однократного введения с постепенно снижающимися скоростями высвобождения
EA201500694A1 (ru) Монолитная лекарственная форма для модифицированного высвобождения комбинации активных ингредиентов
UA110434C2 (en) Dosage form with controlled release and improved stability
MX2011007522A (es) Metodos de tratamiento de la infeccion por el virus del dengue mediante vitamina d.
NZ609720A (en) A pharmaceutical composition with improved storage stability
Rizvi Sexual dysfunction: case report
GR1006419B (el) Παρασκευη φαρμακου με δραστικο συστατικο ουρσολικο οξυ για τη θεραπεια των εγκαυματων